However, they suggest careful evaluation of therapeutic CD4+ T cell products, in regard to donor-dependent variations, as well as TCR affinity and functional avidity testing, in order to avoid possible tumor growth promoting effects. The gene discussed is CD4; the disease is neoplasm.